Access to Medicine Foundation近日发出警示,制药巨头对GLP-1类减肥药物的关注度激增,可能使胰岛素等基本糖尿病治疗药物面临严重的供应风险1。报告分析指出,由于减肥药具有更高的利润空间,诺和诺德、礼来及赛诺菲等行业领军企业可能逐步退出胰岛素市场,这一趋势将对全球糖尿病患者——尤其是中低收入国家的一型糖尿病患者——构成巨大威胁1。
目前,全球约有5.89亿成年人患有糖尿病,其中81%的患者位于中低收入国家1。Access to Medicine Foundation的代表Jay Iyer明确警告,若主要药企撤出胰岛素市场,后果将是灾难性的1。数据显示,在该领域正在研发的25种药物中,仅有10种针对一型糖尿病,反映出研发重心正从传统疗法向肥胖症市场转移1。
尽管整体趋势令人担忧,但部分公司仍在调整其业务布局。诺和诺德已宣布计划逐步淘汰包括胰岛素笔在内的一些较旧糖尿病产品1。与此同时,赛诺菲在德国法兰克福的BioCampus破土动工建设新的胰岛素生产设施,该公司目前仍为超过100个国家的1500万人提供胰岛素1。此外,礼来公司于今年9月获得美国批准,推出了一款新型每周一次注射的胰岛素制剂1。
The Access to Medicine Foundation has warned that the pharmaceutical industry’s growing focus on GLP-1 weight-loss medications could jeopardize the global supply of insulin and other essential diabetes treatments 1. The foundation noted that because weight-loss drugs offer higher profit margins, major manufacturers may withdraw from the insulin market, which would pose a severe threat to medication safety for people with type 1 diabetes globally, especially in low- and middle-income countries (LMICs) 1. Currently, an estimated 589 million adults worldwide live with diabetes, and 81% of them reside in LMICs 1. Jay Iyer cautioned that if companies leave the insulin market, it would be disastrous for supply 1.
While research attention is shifting toward obesity treatments, some companies are maintaining or expanding their involvement in insulin production. Sanofi has broken ground on a new insulin production site at its BioCampus in Frankfurt; the company currently supplies insulin to 15 million people in more than 100 countries 1. Eli Lilly received US approval for a new once-weekly insulin injection in September 1. However, Novo Nordisk has announced plans to phase out some older diabetes products, including insulin pens 1. Furthermore, only 10 of the 25 medications being developed in this area target type 1 diabetes 1.
评论
还没有评论,欢迎留下第一条。